Condition
TAS 102
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Recruiting1
Unknown1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07196345Phase 1Not Yet Recruiting
TAS-102 Plus Radiotherapy in Elderly ESCC
NCT07085169Phase 2Recruiting
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
NCT05993702UnknownPrimary
TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
Showing all 3 trials